$513 Million is the total value of TCG Crossover Management, LLC's 22 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 28.6% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
MDGL | Sell | MADRIGAL PHARMACEUTICALS INC | $36,318,892 | -56.6% | 149,917 | -48.0% | 7.08% | -52.0% |
CBAY | Sell | CYMABAY THERAPEUTICS INC | $26,580,801 | -28.2% | 3,048,257 | -48.4% | 5.18% | -20.7% |
VRDN | Sell | VIRIDIAN THERAPEUTICS, INC | $16,882,238 | -41.2% | 663,610 | -32.5% | 3.29% | -35.1% |
IMVT | Sell | IMMUNOVANT, INC | $10,156,770 | -33.1% | 654,853 | -23.4% | 1.98% | -26.1% |
ACRS | Sell | ACLARIS THERAPEUTICS INC | $4,286,398 | -76.2% | 529,839 | -53.7% | 0.84% | -73.7% |
ELEV | Exit | ELEVATION ONCOLOGY INC | $0 | – | -288,390 | -100.0% | -0.05% | – |
Exit | MOONLAKE IMMUNOTHERAPEUTICS | $0 | – | -1,000,000 | -100.0% | -1.85% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
COGENT BIOSCIENCES INC | 8 | Q3 2023 | 15.6% |
AEROVATE THERAPEUTICS INC | 8 | Q3 2023 | 6.5% |
TYRA BIOSCIENCES INC | 8 | Q3 2023 | 6.2% |
ENTRADA THERAPEUTICS INC | 8 | Q3 2023 | 5.3% |
MERUS N.V. | 8 | Q3 2023 | 3.4% |
IVERIC BIO INC | 7 | Q2 2023 | 24.4% |
Geron Corporation | 7 | Q3 2023 | 12.4% |
ACLARIS THERAPEUTICS INC | 7 | Q2 2023 | 7.9% |
KURA ONCOLOGY INC | 7 | Q3 2023 | 9.1% |
ALPINE IMMUNE SCIENCES INC | 7 | Q2 2023 | 7.6% |
View TCG Crossover Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Silence Therapeutics plc | August 19, 2022 | 6,314,625 | 5.9% |
CymaBay Therapeutics, Inc. | November 29, 2021 | 5,905,400 | 7.0% |
Cogent Biosciences, Inc. | November 17, 2021 | 2,716,042 | 6.8% |
Tyra Biosciences, Inc. | September 29, 2021 | 937,500 | 2.2% |
Viridian Therapeutics, Inc.\DE | September 29, 2021 | 1,314,000 | 8.2% |
View TCG Crossover Management, LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-14 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-14 |
13F-HR | 2023-05-15 |
13F-HR | 2023-02-14 |
13F-HR | 2022-11-14 |
SC 13G | 2022-08-19 |
13F-HR | 2022-08-15 |
13F-HR | 2022-05-16 |
13F-HR | 2022-02-18 |
View TCG Crossover Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.